<PubmedArticle><MedlineCitation Status="PubMed-not-MEDLINE" Owner="NLM"><PMID Version="1">37102167</PMID><DateRevised><Year>2023</Year><Month>04</Month><Day>28</Day></DateRevised><Article PubModel="Electronic-eCollection"><Journal><ISSN IssnType="Electronic">2694-2437</ISSN><JournalIssue CitedMedium="Internet"><Volume>2</Volume><Issue>4</Issue><PubDate><Year>2022</Year><Month>Aug</Month><Day>17</Day></PubDate></JournalIssue><Title>ACS bio &amp; med chem Au</Title><ISOAbbreviation>ACS Bio Med Chem Au</ISOAbbreviation></Journal><ArticleTitle>Efficient Strategy to Design Protease Inhibitors: Application to Enterovirus 71 2A Protease.</ArticleTitle><Pagination><StartPage>437</StartPage><EndPage>449</EndPage><MedlinePgn>437-449</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1021/acsbiomedchemau.2c00001</ELocationID><Abstract><AbstractText>One strategy to counter viruses that persistently cause outbreaks is to design molecules that can specifically inhibit an essential multifunctional viral protease. Herein, we present such a strategy using well-established methods to first identify a region present only in viral (but <i>not</i> human) proteases and find peptides that can bind specifically to this "unique" region by maximizing the protease-peptide binding free energy iteratively using single-point mutations starting with the substrate peptide. We applied this strategy to discover pseudosubstrate peptide inhibitors for the multifunctional 2A protease of enterovirus 71 (EV71), a key causative pathogen for hand-foot-and-mouth disease affecting young children, along with coxsackievirus A16. Four peptide candidates predicted to bind EV71 2A protease more tightly than the natural substrate were experimentally validated and found to inhibit protease activity. Furthermore, the crystal structure of the best pseudosubstrate peptide bound to the EV71 2A protease was determined to provide a molecular basis for the observed inhibition. Since the 2A proteases of EV71 and coxsackievirus A16 share nearly identical sequences and structures, our pseudosubstrate peptide inhibitor may prove useful in inhibiting the two key pathogens of hand-foot-and-mouth disease.</AbstractText><CopyrightInformation>© 2022 The Authors. Published by American Chemical Society.</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Chen</LastName><ForeName>Ting</ForeName><Initials>T</Initials><Identifier Source="ORCID">0000-0001-8055-3104</Identifier><AffiliationInfo><Affiliation>Institute of Biomedical Sciences, Academia Sinica, Taipei 115, Taiwan.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Grauffel</LastName><ForeName>Cédric</ForeName><Initials>C</Initials><Identifier Source="ORCID">0000-0002-9478-4699</Identifier><AffiliationInfo><Affiliation>Institute of Biomedical Sciences, Academia Sinica, Taipei 115, Taiwan.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Yang</LastName><ForeName>Wei-Zen</ForeName><Initials>WZ</Initials><AffiliationInfo><Affiliation>Institute of Molecular Biology, Academia Sinica, Taipei 115, Taiwan.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Chen</LastName><ForeName>Yi-Ping</ForeName><Initials>YP</Initials><AffiliationInfo><Affiliation>Institute of Molecular Biology, Academia Sinica, Taipei 115, Taiwan.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Yuan</LastName><ForeName>Hanna S</ForeName><Initials>HS</Initials><AffiliationInfo><Affiliation>Institute of Molecular Biology, Academia Sinica, Taipei 115, Taiwan.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Lim</LastName><ForeName>Carmay</ForeName><Initials>C</Initials><Identifier Source="ORCID">0000-0001-9077-7769</Identifier><AffiliationInfo><Affiliation>Institute of Biomedical Sciences, Academia Sinica, Taipei 115, Taiwan.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Chemistry, National Tsing Hua University, Hsinchu 300 Taiwan.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2022</Year><Month>04</Month><Day>19</Day></ArticleDate></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>ACS Bio Med Chem Au</MedlineTA><NlmUniqueID>9918232604406676</NlmUniqueID><ISSNLinking>2694-2437</ISSNLinking></MedlineJournalInfo><CoiStatement>The authors declare no competing financial interest.</CoiStatement></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="medline"><Year>2023</Year><Month>4</Month><Day>27</Day><Hour>6</Hour><Minute>43</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2023</Year><Month>4</Month><Day>27</Day><Hour>6</Hour><Minute>42</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2023</Year><Month>4</Month><Day>27</Day><Hour>2</Hour><Minute>17</Minute></PubMedPubDate><PubMedPubDate PubStatus="pmc-release"><Year>2022</Year><Month>4</Month><Day>19</Day></PubMedPubDate></History><PublicationStatus>epublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">37102167</ArticleId><ArticleId IdType="pmc">PMC10125330</ArticleId><ArticleId IdType="doi">10.1021/acsbiomedchemau.2c00001</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Nikonov O. S.; Chernykh E. S.; Garber M. B.; Nikonova E. Y. Enteroviruses: Classification, diseases they cause, and approaches to development of antiviral drugs. Biochemistry (Moscow) 2017, 82 (13), 1615–1631. 10.1134/S0006297917130041.</Citation><ArticleIdList><ArticleId IdType="doi">10.1134/S0006297917130041</ArticleId><ArticleId IdType="pmc">PMC7087576</ArticleId><ArticleId IdType="pubmed">29523062</ArticleId></ArticleIdList></Reference><Reference><Citation>Lin J. Y.; Kung Y. A.; Shih S. R. Antivirals and vaccines for Enterovirus A71. J. Biomed. Sci. 2019, 26, 65.10.1186/s12929-019-0560-7.</Citation><ArticleIdList><ArticleId IdType="doi">10.1186/s12929-019-0560-7</ArticleId><ArticleId IdType="pmc">PMC6720414</ArticleId><ArticleId IdType="pubmed">31481071</ArticleId></ArticleIdList></Reference><Reference><Citation>Wang S. M.; Liu C. C.; Tseng H. W.; Wang J. R.; Huang C. C.; Chen Y. J.; Yang Y. J.; Lin S. J.; Yeh T. F. Clinical Spectrum of Enterovirus 71 Infection in Children in Southern Taiwan, With an Emphasis on Neurological Complications. Clin. Infect. Dis. 1999, 29 (1), 184–190. 10.1086/520149.</Citation><ArticleIdList><ArticleId IdType="doi">10.1086/520149</ArticleId><ArticleId IdType="pubmed">10433583</ArticleId></ArticleIdList></Reference><Reference><Citation>Ryu W. S.; Kang B.; Hong J.; Hwang S.; Kim A.; Kim J.; Cheon D. S. Enterovirus 71 Infection With Central Nervous System Involvement, South Korea. Emerg. Infect. Dis. 2010, 16 (11), 1764–1766. 10.3201/eid1611.100104.</Citation><ArticleIdList><ArticleId IdType="doi">10.3201/eid1611.100104</ArticleId><ArticleId IdType="pmc">PMC3294506</ArticleId><ArticleId IdType="pubmed">21029539</ArticleId></ArticleIdList></Reference><Reference><Citation>Li R.; Liu L.; Mo Z.; Wang X.; Xia J.; Liang Z.; Zhang Y.; Li Y.; Mao Q.; Wang J.; et al. An inactivated enterovirus 71 vaccine in healthy children. N. Eng. J. Med. 2014, 370 (9), 829–837. 10.1056/NEJMoa1303224.</Citation><ArticleIdList><ArticleId IdType="doi">10.1056/NEJMoa1303224</ArticleId><ArticleId IdType="pubmed">24571755</ArticleId></ArticleIdList></Reference><Reference><Citation>Mao Q.; Wang Y.; Bian L.; Xu M.; Liang Z. EV-A71 vaccine licensure: a first step for multivalent enterovirus vaccine to control HFMD and other severe diseases. Emerg. Microbes Infect. 2016, 5 (1), 1–7. 10.1038/emi.2016.73.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/emi.2016.73</ArticleId><ArticleId IdType="pmc">PMC5141264</ArticleId><ArticleId IdType="pubmed">27436364</ArticleId></ArticleIdList></Reference><Reference><Citation>Yi E.-J.; Shin Y.-J.; Kim J.-H.; Kim T.-G.; Chang S.-Y. Enterovirus 71 infection and vaccines. Clin. Exp. Vaccine Res. 2017, 6, 4–14. 10.7774/cevr.2017.6.1.4.</Citation><ArticleIdList><ArticleId IdType="doi">10.7774/cevr.2017.6.1.4</ArticleId><ArticleId IdType="pmc">PMC5292356</ArticleId><ArticleId IdType="pubmed">28168168</ArticleId></ArticleIdList></Reference><Reference><Citation>Baggen J.; Thibaut H. J.; Strating J. R.; van Kuppeveld F. J. The life cycle of non-polio enteroviruses and how to target it. Nat. Rev. Microbiol. 2018, 16 (6), 368–381. 10.1038/s41579-018-0005-4.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41579-018-0005-4</ArticleId><ArticleId IdType="pubmed">29626210</ArticleId></ArticleIdList></Reference><Reference><Citation>Martinez-Gualda B.; Sun L.; Martí-Marí O.; Noppen S.; Abdelnabi R.; Bator C. M.; Quesada E.; Delang L.; Mirabelli C.; Lee H.; et al. Scaffold simplification strategy leads to a novel generation of dual human immunodeficiency virus and enterovirus-A71 entry inhibitors. J. Med. Chem. 2020, 63 (1), 349–368. 10.1021/acs.jmedchem.9b01737.</Citation><ArticleIdList><ArticleId IdType="doi">10.1021/acs.jmedchem.9b01737</ArticleId><ArticleId IdType="pubmed">31809045</ArticleId></ArticleIdList></Reference><Reference><Citation>Bedard K. M.; Semler B. L. Regulation of picornavirus gene expression. Microbes Infect. 2004, 6 (7), 702–713. 10.1016/j.micinf.2004.03.001.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.micinf.2004.03.001</ArticleId><ArticleId IdType="pubmed">15158778</ArticleId></ArticleIdList></Reference><Reference><Citation>Anasir M. I.; Zarif F.; Poh C. L. Antivirals blocking entry of enteroviruses and therapeutic potential. J. Biomed. Sci. 2021, 28, 10.10.1186/s12929-021-00708-8.</Citation><ArticleIdList><ArticleId IdType="doi">10.1186/s12929-021-00708-8</ArticleId><ArticleId IdType="pmc">PMC7811253</ArticleId><ArticleId IdType="pubmed">33451326</ArticleId></ArticleIdList></Reference><Reference><Citation>Gradi A.; Svitkin Y. V.; Imataka H.; Sonenberg N. Proteolysis of human eukaryotic translation initiation factor eIF4GII, but not eIF4GI, coincides with the shutoff of host protein synthesis after poliovirus infection. Proc. Natl. Acad. Sci. U.S.A. 1998, 95, 11089–11094. 10.1073/pnas.95.19.11089.</Citation><ArticleIdList><ArticleId IdType="doi">10.1073/pnas.95.19.11089</ArticleId><ArticleId IdType="pmc">PMC21600</ArticleId><ArticleId IdType="pubmed">9736694</ArticleId></ArticleIdList></Reference><Reference><Citation>Lin J.-Y.; Chen T.-C.; Weng K.-F.; Chang S.-C.; Chen L.-L.; Shih S.-R. Viral and host proteins involved in picornavirus life cycle. J. Biomed. Sci. 2009, 16, 103.10.1186/1423-0127-16-103.</Citation><ArticleIdList><ArticleId IdType="doi">10.1186/1423-0127-16-103</ArticleId><ArticleId IdType="pmc">PMC2785775</ArticleId><ArticleId IdType="pubmed">19925687</ArticleId></ArticleIdList></Reference><Reference><Citation>Lu J.; Yi L.; Zhao J.; Yu J.; Chen Y.; Lin M. C.; Kung H. F.; He M. L. Enterovirus 71 Disrupts Interferon Signaling by Reducing the Level of Interferon Receptor 1. J. Virol. 2012, 86 (7), 3767–3776. 10.1128/JVI.06687-11.</Citation><ArticleIdList><ArticleId IdType="doi">10.1128/JVI.06687-11</ArticleId><ArticleId IdType="pmc">PMC3302529</ArticleId><ArticleId IdType="pubmed">22258259</ArticleId></ArticleIdList></Reference><Reference><Citation>Pathinayake P.; Hsu A.; Wark P. Innate immunity and immune evasion by enterovirus 71. Viruses 2015, 7, 6613–6630. 10.3390/v7122961.</Citation><ArticleIdList><ArticleId IdType="doi">10.3390/v7122961</ArticleId><ArticleId IdType="pmc">PMC4690884</ArticleId><ArticleId IdType="pubmed">26694447</ArticleId></ArticleIdList></Reference><Reference><Citation>Wang J.; Hu Y.; Zheng M. Enterovirus A71 antivirals: Past, present, and future. Acta Pharm. Sin. B 2021, 10.1016/j.apsb.2021.08.017.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.apsb.2021.08.017</ArticleId><ArticleId IdType="pmc">PMC9279511</ArticleId><ArticleId IdType="pubmed">35847514</ArticleId></ArticleIdList></Reference><Reference><Citation>Falah N.; Montserret R.; Lelogeais V.; Schuffenecker I.; Lina B.; Cortay J.-C.; Violot S. b. Blocking human enterovirus 71 replication by targeting viral 2A protease. J. Antimicrob. Chemother. 2012, 67, 2865–2869. 10.1093/jac/dks304.</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/jac/dks304</ArticleId><ArticleId IdType="pubmed">22865380</ArticleId></ArticleIdList></Reference><Reference><Citation>Wang C.-Y.; Huang A.-C.; Hour M.-J.; Huang S.-H.; Kung S.-H.; Chen C.-H.; Chen I.; Chang Y.-S.; Lien J.-C.; Lin C.-W. Antiviral potential of a novel compound CW-33 against enterovirus A71 via inhibition of viral 2A protease. Viruses 2015, 7 (6), 3155–3171. 10.3390/v7062764.</Citation><ArticleIdList><ArticleId IdType="doi">10.3390/v7062764</ArticleId><ArticleId IdType="pmc">PMC4488731</ArticleId><ArticleId IdType="pubmed">26090728</ArticleId></ArticleIdList></Reference><Reference><Citation>Guidotti G.; Brambilla L.; Rossi D. Cell-penetrating peptides: from basic research to clinics. Trends Pharmacol. Sci. 2017, 38, 406–424. 10.1016/j.tips.2017.01.003.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.tips.2017.01.003</ArticleId><ArticleId IdType="pubmed">28209404</ArticleId></ArticleIdList></Reference><Reference><Citation>Drucker D. J. Advances in oral peptide therapeutics. Nat. Rev. Drug Discovery 2020, 19, 277.10.1038/s41573-019-0053-0.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41573-019-0053-0</ArticleId><ArticleId IdType="pubmed">31848464</ArticleId></ArticleIdList></Reference><Reference><Citation>Marchler-Bauer A.; Derbyshire M. K.; Gonzales N. R.; Lu S.; Chitsaz F.; Geer L. Y.; Geer R. C.; He J.; Gwadz M.; Hurwitz D. I.; et al. CDD: NCBI’s conserved domain database. Nucleic Acids Res. 2015, 43 (D1), D222–D226. 10.1093/nar/gku1221.</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/nar/gku1221</ArticleId><ArticleId IdType="pmc">PMC4383992</ArticleId><ArticleId IdType="pubmed">25414356</ArticleId></ArticleIdList></Reference><Reference><Citation>Thompson J. D.; Higgins D. G.; Gibson T. J. CLUSTAL W: Improving the sensitivity of progressive multiple sequence alignments through sequence weighting, position specific gap penalties and weight matrix choice. Nucleic Acids Res. 1994, 22, 4673–4680. 10.1093/nar/22.22.4673.</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/nar/22.22.4673</ArticleId><ArticleId IdType="pmc">PMC308517</ArticleId><ArticleId IdType="pubmed">7984417</ArticleId></ArticleIdList></Reference><Reference><Citation>Berman H.; Henrick K.; Nakamura H. Announcing the worldwide Protein Data Bank. Nat. Struct. Mol. Biol. 2003, 10 (12), 980.10.1038/nsb1203-980.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/nsb1203-980</ArticleId><ArticleId IdType="pubmed">14634627</ArticleId></ArticleIdList></Reference><Reference><Citation>Roy A.; Yang J.; Zhang Y. COFACTOR: an accurate comparative algorithm for structure-based protein function annotation. Nucleic Acids Res. 2012, 40 (W1), W471–W477. 10.1093/nar/gks372.</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/nar/gks372</ArticleId><ArticleId IdType="pmc">PMC3394312</ArticleId><ArticleId IdType="pubmed">22570420</ArticleId></ArticleIdList></Reference><Reference><Citation>Zhang C.; Freddolino P. L.; Zhang Y. COFACTOR: improved protein function prediction by combining structure, sequence and protein-protein interaction information. Nucleic Acids Res. 2017, 45 (W1), W291–W299. 10.1093/nar/gkx366.</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/nar/gkx366</ArticleId><ArticleId IdType="pmc">PMC5793808</ArticleId><ArticleId IdType="pubmed">28472402</ArticleId></ArticleIdList></Reference><Reference><Citation>Ye Y.; Godzik A. FATCAT: a web server for flexible structure comparison and structure similarity searching. Nucleic Acids Res. 2004, 32, W582–W585. 10.1093/nar/gkh430.</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/nar/gkh430</ArticleId><ArticleId IdType="pmc">PMC441568</ArticleId><ArticleId IdType="pubmed">15215455</ArticleId></ArticleIdList></Reference><Reference><Citation>Webb B.; Sali A. Comparative Protein Structure Modeling Using MODELLER. Curr. Protoc. Bioinf. 2016, 54 (1), 5.6.1–5.6.37. 10.1002/cpbi.3.</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/cpbi.3</ArticleId><ArticleId IdType="pmc">PMC5031415</ArticleId><ArticleId IdType="pubmed">27322406</ArticleId></ArticleIdList></Reference><Reference><Citation>Krivov G. G.; Shapovalov M. V.; Dunbrack R. L. Jr Improved prediction of protein side-chain conformations with SCWRL4. Proteins 2009, 77 (4), 778–95. 10.1002/prot.22488.</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/prot.22488</ArticleId><ArticleId IdType="pmc">PMC2885146</ArticleId><ArticleId IdType="pubmed">19603484</ArticleId></ArticleIdList></Reference><Reference><Citation>Olsson M. H. M.; Søndergaard C. R.; Rostkowski M. R.; Jensen J. H. PROPKA3: Consistent treatment of internal and surface residues in empirical pKa predictions. J. Chem. Theory &amp; Comput. 2011, 7 (2), 525–537. 10.1021/ct100578z.</Citation><ArticleIdList><ArticleId IdType="doi">10.1021/ct100578z</ArticleId><ArticleId IdType="pubmed">26596171</ArticleId></ArticleIdList></Reference><Reference><Citation>Brooks B. R.; Brooks III C. L.; Mackerell A. D.; Nilsson L.; Petrella R. J.; Roux B.; Won Y.; Archontis G.; Bartels C.; Boresch S.; Caflisch A.; Caves L.; Cui Q.; Dinner A. R.; Feig M.; Fischer S.; Gao J.; Hodoscek M.; Im W.; Kuczera K.; Lazaridis T.; Ma J.; Ovchinnikov V.; Paci E.; Pastor R. W.; Post C. B.; Pu J. Z.; Schaefer M.; Tidor B.; Venable R. M.; Woodcock H. L.; Wu X.; Yang W.; York D. M.; Karplus M. CHARMM: The Biomolecular Simulation Program. J. Comput. Chem. 2009, 30, 1545–1615. 10.1002/jcc.21287.</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/jcc.21287</ArticleId><ArticleId IdType="pmc">PMC2810661</ArticleId><ArticleId IdType="pubmed">19444816</ArticleId></ArticleIdList></Reference><Reference><Citation>Huang J.; MacKerell A. D. Jr CHARMM36 all-atom additive protein force field: validation based on comparison to NMR data. J. Comput. Chem. 2013, 34 (25), 2135–2145. 10.1002/jcc.23354.</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/jcc.23354</ArticleId><ArticleId IdType="pmc">PMC3800559</ArticleId><ArticleId IdType="pubmed">23832629</ArticleId></ArticleIdList></Reference><Reference><Citation>Jorgensen W. L.; Chandrasekhar J.; Madura J. D.; Impey R. W.; Klein M. L. Comparison of simple potential functions for simulating liquid water. J. Chem. Phys. 1983, 79, 926–935. 10.1063/1.445869.</Citation><ArticleIdList><ArticleId IdType="doi">10.1063/1.445869</ArticleId></ArticleIdList></Reference><Reference><Citation>Phillips J. C.; Braun R.; Wang W.; Gumbart J.; Tajkhorshid E.; Villa E.; Chipot C.; Skeel R. D.; Kalé L.; Schulten K. Scalable molecular dynamics with NAMD. J. Comput. Chem. 2005, 26 (16), 1781–1802. 10.1002/jcc.20289.</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/jcc.20289</ArticleId><ArticleId IdType="pmc">PMC2486339</ArticleId><ArticleId IdType="pubmed">16222654</ArticleId></ArticleIdList></Reference><Reference><Citation>Andersen H. C. RATTLE: a ″velocity″ version of the SHAKE algorithm for molecular dynamics calculations. J. Comput. Phys. 1983, 52, 24–34. 10.1016/0021-9991(83)90014-1.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/0021-9991(83)90014-1</ArticleId></ArticleIdList></Reference><Reference><Citation>Essmann U.; Perera L.; Berkowitz M. L.; Darden T.; Lee H.; Pedersen L. G. A smooth particle mesh Ewald method. J. Chem. Phys. 1995, 103, 8577–8592. 10.1063/1.470117.</Citation><ArticleIdList><ArticleId IdType="doi">10.1063/1.470117</ArticleId></ArticleIdList></Reference><Reference><Citation>Homeyer N.; Gohlke H. Free energy calculations by the molecular mechanics Poisson- Boltzmann surface area method. Mol. Inform. 2012, 31, 114–122. 10.1002/minf.201100135.</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/minf.201100135</ArticleId><ArticleId IdType="pubmed">27476956</ArticleId></ArticleIdList></Reference><Reference><Citation>Wright J. D.; Chu H.-M.; Huang C.-H.; Ma C.; Chang T. W.; Lim C. Structural and physical basis for anti-IgE therapy. Sci. Rep. 2015, 5, 11581.10.1038/srep11581.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/srep11581</ArticleId><ArticleId IdType="pmc">PMC4481376</ArticleId><ArticleId IdType="pubmed">26113483</ArticleId></ArticleIdList></Reference><Reference><Citation>Wang E.; Sun H.; Wang J.; Wang Z.; Liu H.; Zhang J. Z.; Hou T. End-point binding free energy calculation with MM/PBSA and MM/GBSA: Strategies and applications in drug design. Chem. Rev. 2019, 119, 9478–9508. 10.1021/acs.chemrev.9b00055.</Citation><ArticleIdList><ArticleId IdType="doi">10.1021/acs.chemrev.9b00055</ArticleId><ArticleId IdType="pubmed">31244000</ArticleId></ArticleIdList></Reference><Reference><Citation>Forouzesh N.; Mishra N. An Effective MM/GBSA Protocol for Absolute Binding Free Energy Calculations: A Case Study on SARS-CoV-2 Spike Protein and the Human ACE2 Receptor. Molecules 2021, 26, 2383.10.3390/molecules26082383.</Citation><ArticleIdList><ArticleId IdType="doi">10.3390/molecules26082383</ArticleId><ArticleId IdType="pmc">PMC8074138</ArticleId><ArticleId IdType="pubmed">33923909</ArticleId></ArticleIdList></Reference><Reference><Citation>King E.; Aitchison E.; Li H.; Luo R. Recent Developments in Free Energy Calculations for Drug Discovery. Front. Mol. Biosci. 2021, 8, 712085.10.3389/fmolb.2021.712085.</Citation><ArticleIdList><ArticleId IdType="doi">10.3389/fmolb.2021.712085</ArticleId><ArticleId IdType="pmc">PMC8387144</ArticleId><ArticleId IdType="pubmed">34458321</ArticleId></ArticleIdList></Reference><Reference><Citation>Kollman P. A.; Massova I.; Reyes C.; Kuhn B.; Huo S.; Chong L.; Lee M.; Lee T.; Duan Y.; Wang W.; Donini O.; Cieplak P.; Srinivasan J.; Case D. A.; Cheatham III T. E. Calculating structures and free energies of complex molecules: Combining molecular mechanics and continuum models. Acc. Chem. Res. 2000, 33, 889–897. 10.1021/ar000033j.</Citation><ArticleIdList><ArticleId IdType="doi">10.1021/ar000033j</ArticleId><ArticleId IdType="pubmed">11123888</ArticleId></ArticleIdList></Reference><Reference><Citation>Cournia Z.; Allen B.; Sherman W. Relative Binding Free Energy Calculations in Drug Discovery: Recent Advances and Practical Considerations. J. Chem. Inf. Model. 2017, 57, 2911–2937. 10.1021/acs.jcim.7b00564.</Citation><ArticleIdList><ArticleId IdType="doi">10.1021/acs.jcim.7b00564</ArticleId><ArticleId IdType="pubmed">29243483</ArticleId></ArticleIdList></Reference><Reference><Citation>Baker D.; Sali A. Protein structure prediction and structural genomics. Science 2001, 294 (5540), 93–96. 10.1126/science.1065659.</Citation><ArticleIdList><ArticleId IdType="doi">10.1126/science.1065659</ArticleId><ArticleId IdType="pubmed">11588250</ArticleId></ArticleIdList></Reference><Reference><Citation>Sun Y.; Wang X.; Yuan S.; Dang M.; Li X.; Zhang X. C.; Rao Z. An open conformation determined by a structural switch for 2A protease from coxsackievirus A16. Protein Cell 2013, 4, 782–792. 10.1007/s13238-013-3914-z.</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s13238-013-3914-z</ArticleId><ArticleId IdType="pmc">PMC4875437</ArticleId><ArticleId IdType="pubmed">24026848</ArticleId></ArticleIdList></Reference><Reference><Citation>Jumper J.; Evans R.; Pritzel A.; Green T.; Figurnov M.; Ronneberger O.; Tunyasuvunakool K.; Bates R.; Zidek A.; Potapenko A.; Bridgland A.; Meyer C.; Kohl S. A. A.; Ballard A. J.; Cowie A.; Romera-Paredes B.; Nikolov S.; Jain R.; Adler J.; Back T.; Petersen S.; Reiman D.; Clancy E.; Zielinski M.; Steinegger M.; Pacholska M.; Berghammer T.; Bodenstein S.; Silver D.; Vinyals O.; Senior A. W.; Kavukcuoglu K.; Kohli P.; Hassabis D. Highly accurate protein structure prediction with AlphaFold. Nature 2021, 596 (7873), 583–589. 10.1038/s41586-021-03819-2.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41586-021-03819-2</ArticleId><ArticleId IdType="pmc">PMC8371605</ArticleId><ArticleId IdType="pubmed">34265844</ArticleId></ArticleIdList></Reference><Reference><Citation>Cai Q.; Yameen M.; Liu W.; Gao Z.; Li Y.; Peng X.; Cai Y.; Wu C.; Zheng Q.; Li J.; Lin T. Conformational Plasticity of the 2A Proteinase from Enterovirus 71. J. Virol. 2013, 87 (13), 7348–7356. 10.1128/JVI.03541-12.</Citation><ArticleIdList><ArticleId IdType="doi">10.1128/JVI.03541-12</ArticleId><ArticleId IdType="pmc">PMC3700279</ArticleId><ArticleId IdType="pubmed">23616646</ArticleId></ArticleIdList></Reference><Reference><Citation>Falah N.; Violot S.; Décimo D.; Berri F.; Foucault-Grunenwald M.-L.; Ohlmann T.; Schuffenecker I.; Morfin F.; Lina B.; Riteau B.; et al. Ex vivo and in vivo inhibition of human rhinovirus replication by a new pseudosubstrate of viral 2A protease. J. Virol. 2012, 86 (2), 691–704. 10.1128/JVI.05263-11.</Citation><ArticleIdList><ArticleId IdType="doi">10.1128/JVI.05263-11</ArticleId><ArticleId IdType="pmc">PMC3255852</ArticleId><ArticleId IdType="pubmed">22072773</ArticleId></ArticleIdList></Reference><Reference><Citation>Maghsoudi N.; Tafreshi N. K.; Khodagholi F.; Zakeri Z.; Esfandiarei M.; Hadi-Alijanvand H.; Sabbaghian M.; Maghsoudi A. H.; Sajadi M.; Zohri M.; et al. Targeting enteroviral 2A protease by a 16-mer synthetic peptide: inhibition of 2Apro-induced apoptosis in a stable Tet-on HeLa cell line. Virology 2010, 399 (1), 39–45. 10.1016/j.virol.2009.12.017.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.virol.2009.12.017</ArticleId><ArticleId IdType="pubmed">20096913</ArticleId></ArticleIdList></Reference><Reference><Citation>Yang X.; Wang Z.; Xiang Z.; Li D.; Hu Z.; Cui W.; Geng L.; Fang Q. Peptide probes derived from pertuzumab by molecular dynamics modeling for HER2 positive tumor imaging. PLoS Comput. Biol. 2017, 13 (4), e100544110.1371/journal.pcbi.1005441.</Citation><ArticleIdList><ArticleId IdType="doi">10.1371/journal.pcbi.1005441</ArticleId><ArticleId IdType="pmc">PMC5390981</ArticleId><ArticleId IdType="pubmed">28406988</ArticleId></ArticleIdList></Reference><Reference><Citation>Kuo R.-L.; Shih S.-R. Strategies to develop antivirals against enterovirus 71. Virol. J. 2013, 10, 28.10.1186/1743-422X-10-28.</Citation><ArticleIdList><ArticleId IdType="doi">10.1186/1743-422X-10-28</ArticleId><ArticleId IdType="pmc">PMC3614426</ArticleId><ArticleId IdType="pubmed">23339605</ArticleId></ArticleIdList></Reference><Reference><Citation>Budnjo A.; Narawane S.; Grauffel C.; Schillinger A. S.; Fossen T.; Reuter N.; Haug B. E. Reversible ketomethylene-based inhibitors of human neutrophil proteinase 3. J. Med. Chem. 2014, 57 (22), 9396–408. 10.1021/jm500782s.</Citation><ArticleIdList><ArticleId IdType="doi">10.1021/jm500782s</ArticleId><ArticleId IdType="pubmed">25365140</ArticleId></ArticleIdList></Reference><Reference><Citation>Van Kersavond T.; Konopatzki R.; Chakrabarty S.; Blank-Landeshammer B.; Sickmann A.; Verhelst S. H. L. Short Peptides with Uncleavable Peptide Bond Mimetics as Photoactivatable Caspase-3 Inhibitors. Molecules 2019, 24, 206.10.3390/molecules24010206.</Citation><ArticleIdList><ArticleId IdType="doi">10.3390/molecules24010206</ArticleId><ArticleId IdType="pmc">PMC6337261</ArticleId><ArticleId IdType="pubmed">30626051</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle>